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SUMMARY
We present the case of a 34-year-old woman with a
history of antiphospholipid syndrome with triple positivity
for antiphospholipid antibodies, who had multiple
thrombotic events, predominantly pulmonary embolic
events, despite treatment with enoxaparin. She is
currently on warfarin, with which she has been
adequately controlled most of the time, presenting with
only one haemorrhagic event consisting of haematuria
and prolonged international normalised ratio (INR)
without bleeding. This kind of patient represents a
challenge for clinicians, particularly due to INR
therapeutic targets, which should be higher than
recommended in other patients due to the lupus
anticoagulant positivity.
BACKGROUND
Antiphospholipid syndrome (APS) is an auto-
immune disorder characterised by hypercoagulabil-
ity requiring anticoagulant therapy as the basis,
with warfarin as the treatment of choice in cases
requiring long-term management. However,
patients with positive lupus anticoagulant (LA)
present a challenge because they have an increased
risk of thrombotic events, in addition to the fact
that the monitoring of the international normalised
ratio (INR) is unreliable because these antibodies
generate interference with the laboratory tests
based on phospholipids, as is the case for pro-
thrombin time (PT) with prolonged baseline INR,
even before the start of anticoagulant therapy.
For this reason, we present the case of a patient
with primary APS and positive LA who had mul-
tiple thrombotic events despite receiving anticoagu-
lant therapy.
CASE PRESENTATION
We present a case of a 34-year-old woman with gyne-
cobstetric proﬁle G2P1A1V1 and surgical sterilisa-
tion after delivery. She weighed 50 kg. Her ﬁrst
episode of deep venous thrombosis occurred in
2005, after which warfarin therapy was started for
3 years, presenting only a single serious adverse event
of chronic haematuria that led to anaemia, for which
she was hospitalised and transfused with red blood
cells (RBCs). At that time, in 2008, therapy with
enoxaparin 60 mg subcutaneous every 12 h was
started, under which she presented 15 pulmonary
thromboembolism events, despite being adherent to
the therapy. Levels of antifactor Xa were never mea-
sured. For this reason, in May 2012, 20 mg/day oral
rivaroxaban was started, lasting only 3 months, as the
patient presented upper gastrointestinal bleeding
requiring hospitalisation for 45 days, transfusion of
RBCs and administration of prothrombin complex
concentrate. For this reason, she was reverted to
enoxaparin 60 mg SC every 12 h but she presented a
new pulmonary embolism in May 2013. Finally,
therapy with warfarin 2.5–5 mg/day was started,
without new thrombotic or haemorrhagic events to
date. The usual INR prolongations (up to 10) with
no associated bleeding were the only documented
adverse events. The patient mentioned that she had
to change the brand of the drug several times and
follow dietary recommendations to avoid interactions
with food, and that she has not undergone genetic
testing for CYP2C9 and VKORC1.
INVESTIGATIONS
Creatinine (26/07/2013) 0.67 mg/dL.
In 2013, the following immunological proﬁle (09
August 2013) was obtained: antinuclear antibodies:
negative, antiDNA: negative, extractable nuclear anti-
gens: negative, C3: 16 mg/dL, C3: 70 mg/dL.
Anticardiolipin IgG and IgM: positive. Lupus anti-
coagulant IgG and IgM: positive. Anti β2 glycopro-
tein 1 antibodies IgG and IgM: positive.
Baseline INR prior to the start of anticoagulant
therapy is not available.
TREATMENT
In May 2014, the patient underwent
thromboendarterectomy.
She currently receives oxygen 12 h at night with
nasal cannula at 2 L/min from an oxygen tank
▸ Warfarin 5 mg daily
▸ Sildenaﬁl 50 mg every 8 h
▸ Furosemide 40 mg daily
▸ Atorvastatin 40 mg daily
▸ Calcium carbonate 600 mg daily
▸ Carvedilol 6.25 mg every 12 h
▸ Chloroquine 150 mg daily
▸ Spironolactone 25 mg daily
▸ Omeprazole 20 mg daily
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OUTCOME AND FOLLOW-UP
Currently, the patient is stable, with good adherence to treat-
ment and an INR target of 3.0–4.0, without new thrombotic
events since May 2013, in joint management by rheumatology,
internal medicine, pulmonology, anticoagulation clinic, physical
therapy and rehabilitation. After thromboendarterectomy, pul-
monary hypertension has improved, although there is still the
need for supplemental oxygen at night. It should be noted that
pulmonary hypertension occurred because of chronic thrombo-
embolism due to insistent anticoagulation with enoxaparin,
despite the obvious therapeutic failure.
DISCUSSION
APS is an autoimmune disorder characterised by thrombosis
(venous and/or arterial), recurrent abortions and persistently
positive antiphospholipid antibodies (aPL) such as LA, anticar-
diolipin IgG and/or IgM, and/or anti-β2 glycoprotein one anti-
bodies.1 Persistently positive aPL is deﬁned as their presence on
at least two occasions. The second conﬁrmatory APA lab test
should be carried out at least 12 weeks after the initial test.2
APS affects 0.5% of the population and occurs mainly in
young women (only 12% of cases are diagnosed over the age of
50 years) in association with other autoimmune diseases, such
as systemic lupus erythaematosus or lupus-like syndrome (sec-
ondary APS), or in idiopathic form (primary APS).3
Patients with APS have an increased risk of thrombotic events,
and the main therapeutic goal is precisely to prevent such
events; thus, patients with this condition require anticoagulation
for long periods of time,2 4 either as primary or secondary pre-
vention, and warfarin is currently the drug of choice in non-
pregnant patients.3 4
The anticoagulant effect of warfarin is monitored with the
international normalised ratio (INR), which is based on the
patient’s PT.1 The current therapeutic INR target in patients
with APS, according to the anticoagulation guidelines of the
American College of Chest Physicians (CHEST), is between 2.0
and 3.0.5 However, the recommendations are not clear for
patients with APS who are positive for LA, in whom the risk of
thrombosis is higher, as these antibodies mediate the activation
of platelets, monocytes and endothelial cells, causing an inﬂam-
matory process that alters the natural anticoagulant and ﬁbrino-
lytic system.3 Some authors have questioned the targets set by
CHEST due to the limitations and lack of statistical signiﬁcance
of the clinical trial supporting this recommendation, which is
categorised as Grade 2B.3
Additionally, anticoagulation monitoring in LA-positive
patients with APS is problematic because this antibody can
prolong the patient’s baseline INR, even without the patient
having started anticoagulation therapy, and in patients on war-
farin therapy, the INR may be considered supratherapeutic, not
reﬂecting the true state of anticoagulation.1 6 7 Such was the
case in our patient, who had an INR of 7.3 without associated
bleeding. However, the frequency with which LA interferes with
PT is not well established.8
It is proposed that the alteration in the INR is due to the sen-
sitivity of the reagents used in the test to the presence of LA.3
However, some studies show variability in INR with most com-
mercially available reagents.9 Other studies, in contrast, show
that INR results do not vary in the presence of LA, regardless of
the reagent used.10 Therefore, the reliability of INR in this
subtype of patients is uncertain, and the best course of action
must be determined based on the available evidence.
Therefore, there is a need to establish the best anticoagulant
therapy and the best monitoring method in LA-positive patients
with APS.
Low-molecular-weight and unfractionated heparins are effect-
ive in anticoagulant therapy; however, their parenteral adminis-
tration, the risk of heparin-induced thrombocytopenia, and
their association with osteoporosis in prolonged therapy recom-
mend them only at the start of therapy while therapeutic INR
ranges are achieved with warfarin administration.11 According
to The Task Force Report on APS Treatment Trends published
in 2014, current treatment for thrombotic APS consists of
heparin followed by a vitamin K antagonist in the long term.12
In our patient, the use of enoxaparin for 4 years at therapeutic
doses was associated with multiple thromboembolic events, and
for that reason a therapeutic failure of the drug was conﬁrmed,
possibly related to the underlying pathology of the patient.
One group of authors suggests that patients with APS who
present a ﬁrst venous thrombotic event require indeﬁnite antic-
oagulation with warfarin with an INR target of 2.0–3.0.
However, patients with APS presenting one arterial thrombotic
event and/or recurrent thrombotic events, despite treatment
with warfarin reaching an INR between 2.0 and 3.0, should
also receive indeﬁnite anticoagulation with warfarin, but with
an INR target of 3.0–4.0.2 Although these authors do not dif-
ferentiate LA-positive patients with APS, it can be assumed that
these patients can be cast in the second group mentioned.
For primary prevention, these authors suggest the administra-
tion of hydroxychloroquine with low-dose aspirin in
LA-positive patients with APS and/or positive anticardiolipin
antibodies.2 Chloroquine was one of the drugs started in our
patient.
Chromogenic Factor X (CFX) is another phospholipid test
proposed as an alternative for monitoring LA-positive patients
with APS who are being anticoagulated with warfarin.1 3 6 8 In
this test, factor X is activated by Russell’s viper venom in the
presence of calcium; subsequently, factor Xa hydrolyses a highly
speciﬁc chromogenic substrate, producing a yellow pigment ana-
lysed by spectrophotometry at a wavelength of 405 nm.8 CFX
results are reported as a percentage of normal activity of factor
X and are inversely related to INR values. It is considered that
the therapeutic range of CFX is 20–40%; therefore, 40% CFX
would be equivalent to an INR of 2.0 and 20% CFX to an
INR of 3.0.3 7 Although CFX is an attractive alternative to
monitoring LA-positive patients with APS on warfarin therapy,
this test is more expensive than INR, is not readily available,
and its result can only be known 24–72 h after taking the
sample.3
Another alternative for the monitoring of warfarin anticoagu-
lation is factor II. This test is performed based on the patient’s
PT, which may also present variability in the presence of LA,
either by direct interference or due to the presence of anti-
factor II antibodies, which have been documented in
LA-positive patients. When comparing factor II against CFX,
CFX has shown greater precision and stability.6
Rosborough and Shepherd7 compared the activity of CFX
and INR in LA-positive patients versus LA-negative patients,
showing that the therapeutic INR range for LA-positive patients
is higher than currently recommended with reference to the
therapeutic activity of CFX; thus, according to these results, in
these patients, the optimum INR should be between 3.0 and
4.0.2
In many LA-positive patients on warfarin therapy, INR could
be a valid measure of anticoagulation, but it is prudent to valid-
ate this measurement with the concomitant activity of CFX,
2 Baquero-Salamanca M, et al. BMJ Case Rep 2015. doi:10.1136/bcr-2014-209013
Learning from errors
which may be repeated after every cycle of 4–6 INR tests
performed.1 7
One optional treatment for LA-positive patients with APS, in
whom INR monitoring is doubtful, is the use of new oral antic-
oagulants, such as dabigatran, rivaroxaban, apixaban and edoxa-
ban; however, there are no studies supporting the efﬁcacy and
safety of these anticoagulants in these patients. Arachchillage
and Cohen1 advise conducting studies with rivaroxaban because
it is the oral anticoagulant that has been approved in the most
indications (prevention of thrombotic events in patients with
non-valvular atrial ﬁbrillation, treatment and prevention of deep
vein thrombosis and pulmonary embolism, and thromboprophy-
laxis in hip and knee replacement).
Indeed, Bachmeyer and Elalamy13 reported one successful
case of treatment with rivaroxaban at doses of 20 mg daily in a
26-year-old patient with recurrent superﬁcial thrombophlebitis
and primary APS.
Two clinical trials are currently being conducted, TRAPS
(phase III) and RAPS (phase IV). The TRAPS (rivaroxaban in
thrombotic APS) study aims to demonstrate the non-inferiority
of rivaroxaban versus warfarin with respect to the occurrence of
thrombotic events, major bleeding and death in patients with
APS and triple positivity aPL. The RAPS study (rivaroxaban for
APS) aims to monitor a group of patients receiving rivaroxaban
for 1 year and determine the incidence of bleeding and throm-
bosis. The results of these studies are expected in 2018 and
2016, respectively.14 15
We did not ﬁnd a predisposing factor to explain bleeding as
an adverse effect of rivaroxaban in our patient. Among the
drugs that the patient was using at that time (prednisolone,
calcium carbonate, sildenaﬁl, folic acid, omeprazole, alprazo-
lam), drug interactions are not reported.
In conclusion, warfarin remains the drug of choice for long-
term anticoagulant therapy in patients with APS as a second-
ary prevention strategy. However, LA-positive patients with
APS pose a challenge, as they have a higher risk of throm-
botic events, in addition to the fact that they can have a pro-
longed baseline INR, which therefore does not reﬂect the
true state of anticoagulation. All patients with a diagnosis of
APS should have a full aPL proﬁle, and if any antibody is
positive, it should be conﬁrmed at least 12 weeks after the
initial test.
Once the need for anticoagulant therapy is determined, it
must be started with unfractionated or low-molecular-weight
heparin in conjunction with warfarin until therapeutic INR
ranges are obtained. It is important to highlight that the follow-
ing recommendations are perhaps not strongly grounded in evi-
dence, but they are supported by a comprehensive literature
review and perhaps represent the best current consensus
guidelines:
Patients with positive anticardiolipin IgG and/or IgM and/or
anti-β2 glycoprotein 1 antibody, but LA negative and ﬁrst
venous thrombotic event: INR targets should be between 2.0
and 3.0. If the thrombotic event was arterial or recurs despite
treatment with warfarin, INR should be between 3.0 and
4.0.1 2 7
LA-positive patients with prolonged baseline INR, regardless
of the nature of the thrombotic event (primary vs recurrent and
venous vs arterial): INR targets should be between 3.0 and 4.0.
In addition, the activity of CFX should be determined after
every six INR tests performed.1 2 7
LA-positive patients with normal baseline INR and no pro-
longation and ﬁrst venous thrombotic event: INR targets should
be between 2.0 and 3.0.1 2 7
LA-positive patients with normal baseline INR and no pro-
longation but with arterial or recurrent thrombotic event
despite warfarin therapy: INR targets should be between 3.0
and 4.0.
Finally, in triple aPL-positive patients, regardless of the nature
of the thrombotic event suffered and of the prolongation or not of
baseline INR, INR targets should be between 3.0 and 4.0.
Additionally, the activity of CFX should be determined after every
six INR tests performed. We categorise our patient in this group.
Of the therapeutic options currently available for anticoagu-
lant therapy, warfarin is the most effective and safest drug for
use in patients with APS,3 4 provided there is good adherence to
treatment by frequent INR monitoring in an anticoagulation
clinic, together with compliance with dietary recommendations,
using the same brand of drug and avoiding the use of concomi-
tant medications that may interfere with the anticoagulant effect
of warfarin. Similarly, performing genetic testing for CYP2C9
and VKORC1 before the start of therapy is recommended.16
In the case of our patient, it was demonstrated that among all
anticoagulant therapies she received (low-molecular-weight
heparin, inhibitor of activated Factor X and coumarin), warfarin
was the most effective therapy, probably as the result of close
monitoring by the anticoagulation clinic, therefore ensuring her
adherence to therapy. It is unclear why this patient experienced
such a poor response to LMWH and why enoxaparin was used
so many times. We hypothesised that possibly due to the history
of haematuria with warfarin, and since the patient was seen by
different doctors in different institutions between 2008 and
2012, enoxaparin was started many times in spite of repeated
therapeutic failure, becoming an evident medication error.
Results from clinical trials currently underway are expected
and may establish the efﬁcacy and safety of rivaroxaban in
patients with APS.14 15
Learning points
▸ The diagnosis of antiphospholipid syndrome (APS) is
performed in the presence of at least one of the
antiphospholipid antibodies, which should be positive twice
with an interval of at least 12 weeks.
▸ Warfarin remains the therapy of choice for thrombotic APS
in secondary prevention.
▸ Patients with APS and persistently positive lupus
anticoagulant (LA) should have international normalised
ratio (INR) performed before the start of anticoagulant
therapy to detect the prolongation of baseline INR.
▸ The therapeutic targets of LA-positive patients with APS and
prolonged baseline INR, should be between 3.0 and 4.0,
with joint monitoring of the activity of Chromogenic Factor
X after every six INR tests performed.
▸ The efﬁcacy and safety of rivaroxaban in patients with APS
has to be established (pending trial results).
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